Early Diagnosis of Neurodegenerative Diseases by Handwritten Signature Analysis

2015 ◽  
pp. 290-297 ◽  
Author(s):  
Giuseppe Pirlo ◽  
Moises Diaz ◽  
Miguel Angel Ferrer ◽  
Donato Impedovo ◽  
Fabrizio Occhionero ◽  
...  
Keyword(s):  
Early Diagnosis ◽  
Neurodegenerative Diseases ◽  
Signature Analysis ◽  
Handwritten Signature

scholarly journals The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer’s Disease and Parkinson’s Disease

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 371
Author(s):  
Patrycja Pawlik ◽  
Katarzyna Błochowiak
Keyword(s):  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Early Diagnosis ◽  
Neurodegenerative Diseases ◽  
Diagnostic Tool ◽  
Clinical Symptoms ◽  
Early Screening ◽  
Salivary Biomarkers

Many neurodegenerative diseases present with progressive neuronal degeneration, which can lead to cognitive and motor impairment. Early screening and diagnosis of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) are necessary to begin treatment before the onset of clinical symptoms and slow down the progression of the disease. Biomarkers have shown great potential as a diagnostic tool in the early diagnosis of many diseases, including AD and PD. However, screening for these biomarkers usually includes invasive, complex and expensive methods such as cerebrospinal fluid (CSF) sampling through a lumbar puncture. Researchers are continuously seeking to find a simpler and more reliable diagnostic tool that would be less invasive than CSF sampling. Saliva has been studied as a potential biological fluid that could be used in the diagnosis and early screening of neurodegenerative diseases. This review aims to provide an insight into the current literature concerning salivary biomarkers used in the diagnosis of AD and PD. The most commonly studied salivary biomarkers in AD are β-amyloid1-42/1-40 and TAU protein, as well as α-synuclein and protein deglycase (DJ-1) in PD. Studies continue to be conducted on this subject and researchers are attempting to find correlations between specific biomarkers and early clinical symptoms, which could be key in creating new treatments for patients before the onset of symptoms.

The problem of cognitive impairment in neurological practice (reference review)

2014 ◽  
Vol 18 (4 (72)) ◽  
Author(s):  
T. I. Purdenko
Keyword(s):  
Cognitive Impairment ◽  
Early Diagnosis ◽  
Neurodegenerative Diseases ◽  
Old Age ◽  
Cognitive Disorders ◽  
Cerebral Diseases ◽  
Success Of Treatment ◽  
The Brain

The article presents an analysis of the literature on the problem of cognitive disorders. It is in old age, when vascular and neurodegenerative diseases of the brain are most frequently diagnosed, leading to cognitive disorders of varying severity: from mild to severe. Early diagnosis of cerebral diseases increases significantly the chances of success of treatment to the problem.

scholarly journals Plasma-Enabled Carbon Nanostructures for Early Diagnosis of Neurodegenerative Diseases

Materials ◽  
2014 ◽  
Vol 7 (7) ◽  
pp. 4896-4929 ◽  
Author(s):  
Shafique Pineda ◽  
Zhao Han ◽  
Kostya Ostrikov
Keyword(s):  
Early Diagnosis ◽  
Neurodegenerative Diseases ◽  
Carbon Nanostructures

scholarly journals The Evolving Landscape of Exosomes in Neurodegenerative Diseases: Exosomes Characteristics and a Promising Role in Early Diagnosis

2021 ◽  
Vol 22 (1) ◽  
pp. 440
Author(s):  
Simran Rastogi ◽  
Vaibhav Sharma ◽  
Prahalad Singh Bharti ◽  
Komal Rani ◽  
Gyan P. Modi ◽  
...  
Keyword(s):  
Early Diagnosis ◽  
Neurodegenerative Diseases ◽  
Potential Candidate ◽  
Early Disease ◽  
Early Disease Detection ◽  
Specific Proteins ◽  
Disease Initiation ◽  
Non Coding Rnas ◽  
Shed Light

Neurodegenerative diseases (ND) remains to be one of the biggest burdens on healthcare systems and serves as a leading cause of disability and death. Alzheimer’s disease (AD) is among the most common of such disorders, followed by Parkinson’s disease (PD). The basic molecular details of disease initiation and pathology are still under research. Only recently, the role of exosomes has been linked to the initiation and progression of these neurodegenerative diseases. Exosomes are small bilipid layer enclosed extracellular vesicles, which were once considered as a cellular waste and functionless. These nano-vesicles of 30–150 nm in diameter carry specific proteins, lipids, functional mRNAs, and high amounts of non-coding RNAs (miRNAs, lncRNAs, and circRNAs). As the exosomes content is known to vary as per their originating and recipient cells, these vesicles can be utilized as a diagnostic biomarker for early disease detection. Here we review exosomes, their biogenesis, composition, and role in neurodegenerative diseases. We have also provided details for their characterization through an array of available techniques. Their updated role in neurodegenerative disease pathology is also discussed. Finally, we have shed light on a novel field of salivary exosomes as a potential candidate for early diagnosis in neurodegenerative diseases and compared the biomarkers of salivary exosomes with other blood/cerebrospinal fluid (CSF) based exosomes within these neurological ailments.

scholarly journals Omics Data and Their Integrative Analysis to Support Stratified Medicine in Neurodegenerative Diseases

2021 ◽  
Vol 22 (9) ◽  
pp. 4820
Author(s):  
Valentina La Cognata ◽  
Giovanna Morello ◽  
Sebastiano Cavallaro
Keyword(s):  
Early Diagnosis ◽  
Neurodegenerative Diseases ◽  
New Drugs ◽  
Molecular Heterogeneity ◽  
Stratified Medicine ◽  
Treatment Approaches ◽  
Omics Technologies ◽  
Progression Markers ◽  
Design And Testing ◽  
Lateral Sclerosis

Molecular and clinical heterogeneity is increasingly recognized as a common characteristic of neurodegenerative diseases (NDs), such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. This heterogeneity makes difficult the development of early diagnosis and effective treatment approaches, as well as the design and testing of new drugs. As such, the stratification of patients into meaningful disease subgroups, with clinical and biological relevance, may improve disease management and the development of effective treatments. To this end, omics technologies—such as genomics, transcriptomics, proteomics and metabolomics—are contributing to offer a more comprehensive view of molecular pathways underlying the development of NDs, helping to differentiate subtypes of patients based on their specific molecular signatures. In this article, we discuss how omics technologies and their integration have provided new insights into the molecular heterogeneity underlying the most prevalent NDs, aiding to define early diagnosis and progression markers as well as therapeutic targets that can translate into stratified treatment approaches, bringing us closer to the goal of personalized medicine in neurology.

scholarly journals Multi-Layer Picture of Neurodegenerative Diseases: Lessons from the Use of Big Data through Artificial Intelligence

2021 ◽  
Vol 11 (4) ◽  
pp. 280
Author(s):  
Andrea Termine ◽  
Carlo Fabrizio ◽  
Claudia Strafella ◽  
Valerio Caputo ◽  
Laura Petrosini ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Big Data ◽  
Deep Learning ◽  
Early Diagnosis ◽  
Neurodegenerative Diseases ◽  
Neurodegenerative Disorders ◽  
Drug Repurposing ◽  
Biomedical Data ◽  
Parkinson’S Diseases ◽  
Made In

In the big data era, artificial intelligence techniques have been applied to tackle traditional issues in the study of neurodegenerative diseases. Despite the progress made in understanding the complex (epi)genetics signatures underlying neurodegenerative disorders, performing early diagnosis and developing drug repurposing strategies remain serious challenges for such conditions. In this context, the integration of multi-omics, neuroimaging, and electronic health records data can be exploited using deep learning methods to provide the most accurate representation of patients possible. Deep learning allows researchers to find multi-modal biomarkers to develop more effective and personalized treatments, early diagnosis tools, as well as useful information for drug discovering and repurposing in neurodegenerative pathologies. In this review, we will describe how relevant studies have been able to demonstrate the potential of deep learning to enhance the knowledge of neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases through the integration of all sources of biomedical data.

A fluorescent method based on magnetic nanoparticles for detection of CGG trinucleotide repeat genes

2019 ◽  
Vol 43 (3) ◽  
pp. 1322-1327 ◽  
Author(s):  
Ziqi Ren ◽  
Xiaoqian Zhu ◽  
Hehong Lv ◽  
Heng Liu ◽  
Hanping He ◽  
...  
Keyword(s):  
Magnetic Nanoparticles ◽  
Early Diagnosis ◽  
Neurodegenerative Diseases ◽  
Linear Correlation ◽  
High Selectivity ◽  
Trinucleotide Repeat ◽  
Fluorescent Sensor ◽  
Trinucleotide Repeats ◽  
Short Report ◽  
Fluorescent Method

A novel fluorescent sensor based on magnetic nanoparticles as the separator and short report DNA was designed and prepared for the detection of d(CGG)ntrinucleotide repeats. The method exhibited high selectivity and sensitivity, and excellent linear correlation from 100 pM to 150 nM, which is useful for the early diagnosis of neurodegenerative diseases.

Sign in / Sign up

Export Citation Format

Share Document